Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Telix’s Illucix Approved by Danish Medicines Agency | Contract Pharma

What are you searching for?

Sign in
Breaking News

Telix’s Illucix Approved by Danish Medicines Agency

Danish physicians and their patients will now have access to Telix's gallium-based PSMA-PET imaging agent.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Image courtesy of Tung Lam from Pixabay.

Telix Pharmaceuticals Ltd.’s prostate cancer PET imaging agent Illuccix has been approved by the Danish Medicines Agency.

Illuccix, after radiolabelling with gallium-68, is indicated in Denmark for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings:

Primary staging of patients with high-risk PCa prior to primary curative therapy.

Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy.

Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated.

PSMA-PET imaging is a major advancement in prostate cancer care, replacing conventional methods like bone and CT scans after diagnosis and biochemical recurrence (BCR). Global guidelines underscore PSMA-PET’s superior accuracy for staging primary disease and assessing BCR/biochemical persistence (BCP). Illuccix PSMA-PET addresses an unmet need for timely diagnosis and patient selection for PSMA-targeted therapy.

Raphaël Ortiz, Chief Executive Officer, Telix International, commented, “We are delighted that Illuccix has been approved in Denmark with this broad label demonstrative of clinical utility at multiple critical points in the prostate cancer journey. Danish physicians and their patients will now have access to Telix’s innovative gallium-based PSMA-PET imaging agent, along with the efficiencies and scheduling flexibility of generator-produced gallium.”

Illuccix will be made available in Denmark through Telix’s distribution partner for the Nordic region, WIIK Pharma ApS (WIIk Pharma).

More Telix News

Telix recently entered into an asset purchase agreement with ImaginAb Inc. to acquire a pipeline of next-gen therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics